We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

300390:SZSECanmax Technologies Co., Ltd. Class A Analysis

Data as of 2026-03-12 - not real-time

CN¥51.33

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Canmax Technologies is trading at CNY 51.33, well above its 20‑day SMA of 47.77 and the DCF‑derived fair value of roughly CNY 22, indicating a significant premium. The stock sits comfortably above its technical support at CNY 42.89 but below the resistance level of CNY 56, with a bullish MACD histogram (+0.47) and an RSI of 57 suggesting modest upward momentum. However, volume is on a decreasing trend and 30‑day volatility is extremely high at over 60%, while beta is near zero (0.08), implying price swings are driven more by company‑specific factors than market moves. Fundamentally, the company posted a revenue growth of 21.5% yet recorded a negative profit margin (‑0.6%) and a trailing EPS of ‑0.05, with a forward EPS of 1.64 that still leaves the forward PE at 31.3 versus an industry average of 29.9. The balance sheet shows a high debt‑to‑equity ratio of 24.5 and negative free cash flow, while the dividend payout ratio exceeds 200%, making the current 1.17% yield unsustainable. Overall, the market price reflects aggressive speculation rather than intrinsic value, and the combination of weak earnings, high leverage, and elevated volatility raises concerns for investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • price trading above short‑term support
  • bullish MACD histogram
  • high volatility may cause short‑term swings

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • DCF fair value far below market price
  • negative earnings and cash flow
  • elevated debt level

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • fundamental turnaround unlikely
  • valuation gap unsustainable
  • regulatory and sector headwinds

Key Metrics & Analysis

Financial Health

Revenue Growth21.50%
Profit Margin-0.64%
P/E Ratio31.3
ROE-0.55%
ROA-0.72%
Debt/Equity24.52
P/B Ratio3.9
Op. Cash FlowCN¥826.7M
Free Cash FlowCN¥-2936613632
Industry P/E30.0

Technical Analysis

TrendNeutral
RSI57.3
SupportCN¥42.89
ResistanceCN¥56.00
MA 20CN¥47.77
MA 50CN¥50.37
MA 200CN¥33.26
MACDBullish
VolumeDecreasing
Fear & Greed Index78.16

Valuation

Fair ValueCN¥21.97
Target PriceCN¥24.28
Upside/Downside-52.70%
GradeOvervalued
TypeBlend
Dividend Yield1.17%

Risk Assessment

Beta0.08
Volatility60.25%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.